Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 112

Sort by

Sort Order Select

Journal Articles

Single- and double-hit events in genes encoding immune targets before and after T cell–engaging antibody therapy in MM

Blood Adv (2021) 5 (19): 3794–3798.

https://doi.org/10.1182/bloodadvances.2021004418

Published: 2021

Includes: Supplemental data

Journal Articles

The selection of variable regions affects effector mechanisms of IgA antibodies against CD20

Mitchell Evers, Thies Rösner, Anna Dünkel, J. H. Marco Jansen, Niklas Baumann, Toine ten Broeke, Maaike Nederend, Klara Eichholz, Katja Klausz, Karli Reiding, Denis M. Schewe, Christian Kellner, Matthias Peipp, Jeanette H. W. Leusen, Thomas Valerius

Blood Adv (2021) 5 (19): 3807–3820.

https://doi.org/10.1182/bloodadvances.2021004598

Published: 2021

Includes: Supplemental data

Journal Articles

Thrombosis and novel hemophilia therapies: the fine line between clotting and bleeding

Maureane Hoffman

Blood Adv (2021) 5 (18): 3736.

https://doi.org/10.1182/bloodadvances.2021004802

Published: 2021

Includes: Supplemental data

Journal Articles

The promise and perils of immunotherapy

Stefanie Lesch, Saar Gill

Blood Adv (2021) 5 (18): 3709–3725.

https://doi.org/10.1182/bloodadvances.2021004453

Published: 2021

Journal Articles

Physiologic IGFBP7 levels prolong IGF1R activation in acute lymphoblastic leukemia

Leonardo Luís Artico, Angelo Brunelli Albertoni Laranjeira, Livia Weijenborg Campos, Juliana Ronchi Corrêa, Priscila Pini Zenatti, José Barreto Campello Carvalheira, Sandra Regina Brambilla, Alexandre Eduardo Nowill, Silvia Regina Brandalise, José Andrés Yunes

Blood Adv (2021) 5 (18): 3633–3646.

https://doi.org/10.1182/bloodadvances.2020003627

Published: 2021

Includes: Supplemental data

Journal Articles

Preclinical evaluation of immunotherapeutic regimens for fetal/neonatal alloimmune thrombocytopenia

Huiying Zhi, Maria T. Ahlen, Björn Skogen, Debra K. Newman, Peter J. Newman

Blood Adv (2021) 5 (18): 3552–3562.

https://doi.org/10.1182/bloodadvances.2021004371

Published: 2021

Includes: Supplemental data

Journal Articles

The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1 + leukemia

Blood Adv (2021) 5 (16): 3152–3162.

https://doi.org/10.1182/bloodadvances.2020003276

Published: 2021

Includes: Supplemental data

Journal Articles

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma

C. Perry, E. Luttwak, R. Balaban, G. Shefer, M. M. Morales, A. Aharon, Y. Tabib, Y. C. Cohen, N. Benyamini, O. Beyar-Katz, M. Neaman, R. Vitkon, N. Keren-Khadmy, M. Levin, Y. Herishanu, I. Avivi

Blood Adv (2021) 5 (16): 3053–3061.

https://doi.org/10.1182/bloodadvances.2021005094

Published: 2021

Journal Articles

Effective anti-BCMA retreatment in multiple myeloma

Nicolas Gazeau, David Beauvais, Ibrahim Yakoub-Agha, Suman Mitra, Timothy B. Campbell, Thierry Facon, Salomon Manier

Blood Adv (2021) 5 (15): 3016–3020.

https://doi.org/10.1182/bloodadvances.2021004176

Published: 2021

Journal Articles

Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment

Blood Adv (2021) 5 (15): 2945–2957.

https://doi.org/10.1182/bloodadvances.2021004770

Published: 2021

Includes: Supplemental data

Journal Articles

Continuous-infusion von Willebrand factor concentrate is effective for the management of acquired von Willebrand disease

Kathryn E. Dane, John P. Lindsley, Thomas Kickler, Michael B. Streiff, Alison Moliterno, Jennifer Yui, Rakhi Naik, Shruti Chaturvedi

Blood Adv (2021) 5 (14): 2813–2816.

https://doi.org/10.1182/bloodadvances.2021004843

Published: 2021

Journal Articles

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

Blood Adv (2021) 5 (13): 2707–2716.

https://doi.org/10.1182/bloodadvances.2020004155

Published: 2021

Includes: Supplemental data

Journal Articles

A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2

Anne Louise Tølbøll Sørensen, Magalie Rolland, Jacob Hartmann, Zitta Barrella Harboe, Casper Roed, Tomas Ø. Jensen, Lilian Kolte, Daniel El Fassi, Jens Hillingsø, Aneta Radziwon-Balicka, Robert Sebastian Soyka, Klaus Hansen, Nikolai Kirkby, Jens P. Goetze, Mikkel Gybel-Brask, Eva Birgitte Leinøe, Anne-Mette Hvas, Peter Kampmann, Jakob Stensballe

Blood Adv (2021) 5 (12): 2569–2574.

https://doi.org/10.1182/bloodadvances.2021004904

Published: 2021

Journal Articles

Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR -mutated MPNs

Manjola Balliu, Laura Calabresi, Niccolò Bartalucci, Simone Romagnoli, Laura Maggi, Rossella Manfredini, Matteo Lulli, Paola Guglielmelli, Alessandro Maria Vannucchi

Blood Adv (2021) 5 (8): 2184–2195.

https://doi.org/10.1182/bloodadvances.2020003291

Published: 2021

Includes: Supplemental data

Journal Articles

Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma

Hilma J. van der Horst, Anne T. Gelderloos, Martine E. D. Chamuleau, Esther C. W. Breij, Sonja Zweegman, Inger S. Nijhof, Marije B. Overdijk, Tuna Mutis

Blood Adv (2021) 5 (8): 2165–2172.

https://doi.org/10.1182/bloodadvances.2020003731

Published: 2021

Includes: Supplemental data

Journal Articles

Activity of blinatumomab in lymphoblastic leukemia with impaired T-cell immunity due to congenital immunodeficiency

Sandheeah Ramdeny, Asima Chaudhary, Austen Worth, Sara Ghorashian, Mary Slatter, Su Han Lum, Ajay Vora

Blood Adv (2021) 5 (8): 2153–2155.

https://doi.org/10.1182/bloodadvances.2021004284

Published: 2021

Journal Articles

Heme activates platelets and exacerbates rhabdomyolysis-induced acute kidney injury via CLEC-2 and GPVI/FcRγ

Saori Oishi, Nagaharu Tsukiji, Shimon Otake, Naoki Oishi, Tomoyuki Sasaki, Toshiaki Shirai, Yuri Yoshikawa, Katsuhiro Takano, Hideyuki Shinmori, Takeshi Inukai, Tetsuo Kondo, Katsue Suzuki-Inoue

Blood Adv (2021) 5 (7): 2017–2026.

https://doi.org/10.1182/bloodadvances.2020001698

Published: 2021

Includes: Supplemental data

Journal Articles

Autoimmune hypoglycemia expands the biological spectrum of HHV8 + multicentric Castleman disease

Pierre Arnautou, Martine Auclair, Soraya Fellahi, Clara Bouché, Claire Fieschi, Elias Barrak, Viviane Queyrel-Moranne, Lucy Chaillous, Nicolas Blin, Marion Malphettes, Jehane Fadlallah, Remi Bertinchamp, Laurence Gérard, Djaouida Bengoufa, Lionel Galicier, Eric Oksenhendler, Corinne Vigouroux, David Boutboul

Blood Adv (2021) 5 (7): 1848–1852.

https://doi.org/10.1182/bloodadvances.2020002801

Published: 2021

Includes: Supplemental data

Journal Articles

Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma

Harsh Parmar, Morie Gertz, Emilie Ingrid Anderson, Shaji Kumar, Taxiarchis V. Kourelis

Blood Adv (2021) 5 (7): 1797–1804.

https://doi.org/10.1182/bloodadvances.2020003857

Published: 2021

Includes: Supplemental data

Journal Articles

A BCMAxCD3 bispecific T cell–engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells

David J. DiLillo, Kara Olson, Katja Mohrs, Thomas Craig Meagher, Kevin Bray, Olga Sineshchekova, Thomas Startz, Jessica Kuhnert, Marc W. Retter, Stephen Godin, Prachi Sharma, Frank Delfino, John Lin, Eric Smith, Gavin Thurston, Jessica R. Kirshner

Blood Adv (2021) 5 (5): 1291–1304.

https://doi.org/10.1182/bloodadvances.2020002736

Published: 2021

Includes: Supplemental data

NARROW

Single- and double-hit events in genes encoding immune targets before and after T cell–engaging antibody therapy in MM

The selection of variable regions affects effector mechanisms of IgA antibodies against CD20

Thrombosis and novel hemophilia therapies: the fine line between clotting and bleeding

The promise and perils of immunotherapy

Physiologic IGFBP7 levels prolong IGF1R activation in acute lymphoblastic leukemia

Preclinical evaluation of immunotherapeutic regimens for fetal/neonatal alloimmune thrombocytopenia

The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1 + leukemia

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma

Effective anti-BCMA retreatment in multiple myeloma

Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment

Continuous-infusion von Willebrand factor concentrate is effective for the management of acquired von Willebrand disease

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2

Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR -mutated MPNs

Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma

Activity of blinatumomab in lymphoblastic leukemia with impaired T-cell immunity due to congenital immunodeficiency

Heme activates platelets and exacerbates rhabdomyolysis-induced acute kidney injury via CLEC-2 and GPVI/FcRγ

Autoimmune hypoglycemia expands the biological spectrum of HHV8 + multicentric Castleman disease

Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma

A BCMAxCD3 bispecific T cell–engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only